Network meta-analysis of progression free survival in the treatment of relapsed or refractory chronic lymphocytic leukemia.

被引：0
|
作者：
Chanan-Khan, Asher
Liu, Tom
Yang, Keri
Cohen, Aileen
Fahrbach, Kyle
Campbell, Joanna
Tang, Boxiong
机构：
[1] Mayo Clin, Jacksonville, FL USA
[2] BeiGene Inc, San Mateo, CA USA
[3] Evidera, Lexington, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
19514
引用
收藏
页数：1
相关论文
共 50 条
  • [21] COMPARATIVE BAYESIAN NETWORK META-ANALYSIS OF BTKI-SPECIFIC ADVERSE EVENTS IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
    Monica, M.
    Reczek, M.
    Kawalec, P.
    VALUE IN HEALTH, 2024, 27 (06) : S29 - S30
  • [22] Ofatumumab in combination with high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia.
    Castro, Januario E.
    Choi, Michael Y.
    Carvajal, Tomas
    Li, Hongying
    James, Danelle Frances
    Messer, Karen
    Kipps, Thomas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [23] The role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemia
    Nair, Kruti Sheth
    Cheson, Bruce
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2016, 7 (02) : 69 - 84
  • [24] CLADRIBINE IN THE TREATMENT OF RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC-LEUKEMIA
    TALLMAN, MS
    HAKIMIAN, D
    ZANZIG, C
    HOGAN, DK
    RADEMAKER, A
    ROSE, E
    VARIAKOJIS, D
    JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (04) : 983 - 988
  • [25] PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN RELAPSED-REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA
    Amin, A.
    Taylor, R.
    Alonso, A.
    Schwenke, C.
    Gaudig, M.
    Gaugris, S.
    Welten, H.
    Erhardt, W.
    Roberts, G.
    O'Leary, M.
    Wasserman, M.
    HAEMATOLOGICA, 2014, 99 : 591 - 591
  • [26] Real world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: a meta-analysis of clinical studies
    Karimi, Mohammad Amin
    Norooziseyedhosseini, Hanieh
    Khademi, Reza
    Ghajary, Alireza
    Kargar, Haniyeh
    Abdollahi, Seyyedeh Sana
    Belbasi, Mohaddeseh
    Naziri, Mahdyieh
    Deravi, Niloofar
    Hajihosseini, Sajjad
    Mofidi, Saharnaz
    BMC PHARMACOLOGY & TOXICOLOGY, 2025, 26 (01):
  • [27] Treatment Outcomes of Novel Targeted Agents in Relapse/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-Analysis
    Chen, Po-Huang
    Ho, Ching-Liang
    Lin, Chin
    Wu, Yi-Ying
    Huang, Tzu-Chuan
    Tu, Yu-Kang
    Lee, Cho-Hao
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (05)
  • [28] A network meta-analysis of maintenance therapy in chronic lymphocytic leukemia
    Lee, Cho-Hao
    Chen, Po-Huang
    Lin, Chin
    Wang, Chieh-Yung
    Ho, Ching-Liang
    PLOS ONE, 2020, 15 (01):
  • [29] PRACTICAL MANAGEMENT AND CARE FOR PATIENTS TAKING VENETOCLAX FOR RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA.
    Battiato, Kristen
    Paradis, Heather Brumbaugh
    Alton, Peggy
    Alter, Debbie
    Miale-Mayer, Donna
    Llerandi, Diane
    ONCOLOGY NURSING FORUM, 2017, 44 (02)
  • [30] Venetoclax alone or in combination with other regimens treatment achieve deep and sustained remission of relapsed/refractory chronic lymphocytic leukemia: a meta-analysis
    Xiao Tang
    Wenrong Zou
    Peng Peng
    Yanglu Bai
    Clinical and Experimental Medicine, 2022, 22 : 161 - 171
12345